Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors

Nature Communications

Volumn 8, Issue 1, 2017, Pages

  Sykes, David A ^a   Moore, Holly ^b,c   Stott, Lisa ^a   Holliday, Nicholas ^a   Javitch, Jonathan A ^b,c   Robert Lane, J ^d   Charlton, Steven J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Columbia University ^*  (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ASENAPINE; CHLORPROMAZINE; CLOZAPINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; DROPERIDOL; EMONAPRIDE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LOXAPINE; MELPERONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PROLACTIN; QUETIAPINE; RACLOPRIDE; RADIOLIGAND; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; SPIPERONE; THIORIDAZINE; TRIFLUOPERAZINE; ZIPRASIDONE; ZOTEPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DRD2 PROTEIN, HUMAN;

DRUG; EXPERIMENTAL STUDY; HYPOTHESIS TESTING; PROTEIN; REACTION KINETICS;

ARTICLE; BINDING KINETICS; BINDING SITE; EXTRAPYRAMIDAL SYMPTOM; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; MICROENVIRONMENT; RECEPTOR BLOCKING; ANIMAL; CHEMICALLY INDUCED; CHO CELL LINE; CRICETULUS; EXTRAPYRAMIDAL SYNDROME; HYPERPROLACTINEMIA; METABOLISM;

ANIMALS; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHO CELLS; CRICETULUS; DOPAMINE ANTAGONISTS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; HYPERPROLACTINEMIA; RECEPTORS, DOPAMINE D2;

EID: 85030563102     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-017-00716-z     Document Type: Article

References (70)

1. Ginovart, N. & Kapur, S. Role of dopamine D(2) receptors for antipsychotic activity. Handb. Exp. Pharmacol. 212, 27-52 (2012).
2. Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W. & Lieberman, J. A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17, 1206-1227 (2012).
3. Meltzer, H. Y. Update on typical and atypical antipsychotic drugs. Annu. Rev. Med. 64, 393-406 (2013).
4. Leucht, S. et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373, 31-41 (2009).
5. Farde, L. et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 49, 538-544 (1992).
6. 3H]dihydroergocryptine binding with the dopaminergic control of prolactin release. J. Biol. Chem. 253, 2244-2253 (1978).
7. Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238-246 (1989).
8. Perkins, D. O. Predictors of noncompliance in patients with schizophrenia. J. Clin. Psychiatry 63, 1121-1128 (2002).
9. Janssen, P. A. et al. Pharmacology of risperidone (R 64,766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J. Pharmacol. Exp. Ther. 244, 685-693 (1998).
10. Meltzer, H. Y., Matsubara, S. & Lee, J. C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251, 238-246 (1989).
11. Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359 (2004).
12. Martinot, J. L. et al. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124, 154-158 (1996).
13. Kapur, S. & Seeman, P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 158, 360-369 (2001).
14. Burki, H. R. Effects of fluperlapine on dopaminergic systems in rat brain. Psychopharmacology 89, 77-84 (1986).
15. Seeman, P., Corbett, R., Nam, D. & Van Tol, H. H. M. Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic parkinsonism. Jpn J. Pharmacol. 71, 187-204 (1996).
16. Seeman, P., Corbett, R. & Van Tol, H. H. M. Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacol 16, 93-110 (1997).
17. Seeman, P. & Tallerico, T. Antipsychotic drugs which elicit little or no parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry 3, 123-134 (1998).
18. Seeman, P. & Tallerico, T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J. Psychiatry 156, 876-884 (1999).
19. Kapur, S. & Seeman, P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25, 161-166 (2000).
20. Charlton, S. J. & Vauquelin, G. Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br. J. Pharmacol. 161, 1250-1265 (2010).
21. Klein Herenbrink, C. et al. The role of kinetic context in apparent biased agonism at GPCRs. Nat. Commun. 7, 10842 (2016).
22. Rice, M. E. & Cragg, S. J. Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res. Rev. 58, 303-313 (2008).
23. Lagerholm, B. C. & Thompson, N. L. Theory for ligand rebinding at cell membrane surfaces. Biophys. J. 74, 1215-1228 (1998).
24. Vauquelin, G. & Charlton, S. J. Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action. Br. J. Pharmacol. 161, 488-508 (2010).
25. Langlois, X. et al. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia. J. Pharmacol. Exp. Ther. 342, 91-105 (2012).
26. Motulsky, H. J. & Mahan, L. C. The kinetics of competitive radioligand binding predicted by the law of mass action. Mol. Pharmacol. 25, 1-9 (1984).
27. Carboni, L. et al. Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release. Int. J. Neuropsychopharmacol. 15, 645-656 (2012).
28. Albizu, L. et al. Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 6, 587-594 (2010).
29. Seeman, P. An update of fast-off dopamine D2 atypical antipsychotics. Am. J. Psychiatry 162, 1984-1985 (2005).
30. Seeman, P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47, 27-38 (2000).
31. Leucht, S. et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951-962 (2013).
32. Shapiro, D. A. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411 (2003).
33. Yokoi, F. et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 27, 248-259 (2002).
34. Tarazi, F. I., Zhang, K. & Baldessarini, R. J. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J. Pharmacol. Exp. Ther. 297, 711-717 (2001).
35. Ribrault, C., Sekimoto, K. & Triller, A. From the stochasticity of molecular processes to the variability of synaptic transmission. Nat. Rev. Neurosci. 12, 375-387 (2011).
36. Descarries, L., Watkins, K. C., Garcia, S., Bosler, O. & Doucet, G. Dual character, asynaptic and synaptic, of the dopamine innervation in adult rat neostriatum: a quantitative autoradiographic and immunocytochemical analysis. J. Comp. Neurol. 375, 167-186 (1996).
37. Roth, B. L., Sheffler, D. & Potkine, S. G. Atypical antipsychotic drug actions: unitary or multiple mechanisms for 'atypicality'? Clin. Neurosci. Res. 3, 108-117 (2003).
38. Horacek, J. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20, 389-409 (2006).
39. Sahlholm, K. et al. Typical and atypical antipsychotics do not differ markedly in their reversibility of antagonism of the dopamine D2 receptor. Int. J. Neuropsychopharmacol. 17, 149-155 (2013).
40. Sahlholm, K. et al. The fast-off hypothesis revisited: a functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor. Eur. Neuropsychopharmacol. 26, 467-476 (2016).
41. Newman-Tancredi, A. & Kleven, M. S. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties. Psychopharmacology 216, 451-473 (2011).
42. MacLeod, R. M., Fontham, E. H. & Lehmeyer, J. E. Prolactin and growth hormone production as influenced by catecholamines and agents that affect brain catecholamines. Neuroendocrinology 6, 283-294 (1970).
43. Kamberi, I. A., Mical, R. S. & Porter, J. C. Prolactin-inhibiting activity in hypophysial stalk blood and elevation by dopamine. Experientia 26, 1150-1151 (1970).
44. Mansour, A. et al. Localization of dopamine D2 receptor mRNA and D1 and D2 receptor binding in the rat brain and pituitary: an in situ hybridization receptor autoradiographic analysis. J. Neurosci. 10, 2587-2600 (1990).
45. Asmal, L. et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev. 11, CD006625 (2013).
46. Handley, S. A., Bowskill, S. V., Patel, M. X. & Flanagan, R. J. Plasma quetiapine in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 2000-2011. Ther. Adv. Psychopharmacol 3, 129-137 (2013).
47. Carter, C. M., Leighton-Davies, J. R. & Charlton, S. J. Miniaturized receptor binding assays: complications arising from ligand depletion. J. Biomol. Screen. 12, 255-266 (2007).
48. Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108 (1973).
49. Coombs, D. & Goldstein, B. Effects of the geometry of the immunological synapse on the delivery of effector molecules. Biophys. J. 87, 2215-2220 (2004).
50. Crespo-Facorro, B. et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. J. Psychopharmacol. 25, 744-754 (2011).
51. Cuesta, M. J. et al. Spontaneous parkinsonism is associated with cognitive impairment in antipsychotic-naive patients with first-episode psychosis: a 6-month follow-up study. Schizophr. Bull. 40, 1164-1173 (2014).
52. Kahn, R. S. et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085-1097 (2008).
53. Lieberman, J. A. et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28, 995-1003 (2003).
54. Moller, H. J. et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German research network on Schizophrenia. Int. J. Neuropsychopharmacol. 11, 985-997 (2008).
55. Robinson, D. G. et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am. J. Psychiatry 163, 2096-2102 (2006).
56. Sanger, T. M. et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am. J. Psychiatry 156, 79-87 (1999).
57. Schooler, N. et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 162, 947-953 (2005).
58. Chakrabarti A. et al. Loxapine for schizophrenia. Cochrane Database Syst. Rev. CD001943 4, CD001943 (2007).
59. Glazer, W. M. Does loxapine have "atypical" properties? Clinical evidence. J. Clin. Psychiatry 60, 42-46 (1999).
60. Peluso, M. J., Lewis, S. W., Barnes, T. R. & Jones, P. B. Extrapyramidal motor side-effects of first-and second-generation antipsychotic drugs. Br. J. Psychiatry 200, 387-392 (2012).
61. Kose, E., Uno, K. & Hayashi, H. Evaluation of the expression profile of extrapyramidal symptoms due to antipsychotics by data mining of Japanese adverse drug event report (JADER) database. Yakugaku. Zasshi. 137, 111-120 (2017).
62. Tandon, R. et al. Section of pharmacopsychiatry, world psychiatric association pharmacopsychiatry section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 100, 20-38 (2008).
63. Röhricht, F., Gadhia, S., Alam, R. & Willis, M. Auditing clinical outcomes after introducing off-licence prescribing of atypical antipsychotic melperone for patients with treatment refractory schizophrenia. Sci. World J. 2012, 512047 (2012).
64. Popovic, D., Nuss, P. & Vieta, E. Revisiting loxapine: a systematic review. Ann. Gen. Psychiatry. 14, 15 (2015).
65. Bagnall, A., Fenton, M., Lewis, R., Leitner, M. L. & Kleijnen, J. Molindone for schizophrenia and severe mental illness. J.Cochrane Database Syst. Rev. 2, CD002083 (2002).
66. Aparasu, R. R., Jano, E., Johnson, M. L. & Chen, H. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients. Am. J. Geriatr. Pharmacother. 6, 198-204 (2008).
67. Sikich, L. et al. Double-blind comparison of first-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am. J. Psychiatry. 165, 1420-1431 (2008).
68. Hemsley, K. M. & Crocker, A. D. Raclopride and chlorpromazine, but not clozapine, increase muscle rigidity in the rat: relationship with D2 dopamine receptor occupancy. Neuropsychopharmacology 21, 101-109 (1999).
69. Stone T. W. CNS Neurotransmitters and Neuromodulators: Dopamine (CRC Press, 1996).
70. Westerink, B. H. Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur. J. Pharmacol. 455, 1-18 (2002).